Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial." (Www.E-P-A.Org)
Care pathways, a complex intervention to (re)organise, standardize and evaluate care
processes, are used worldwide and in different kinds of settings. Although their
international use, the impact is unclear. The European Quality of Care Pathways Study is the
first international cluster Randomized Controlled Trial on the effect of care pathways for
COPD patients.
The hypothesis is that teams who work with care pathways for COPD patients deliver care that
is more compliant to evidence based key interventions, have better patient outcomes and
higher scores on team indicators than teams who do not work with care pathways.
Healthcare is changing towards more patient focused care. The organization of the care
process related to quality, efficiency and accessibility is one of the main areas of interest
within the next years for clinicians, healthcare managers and policy makers. A main method to
(re)organize a care process is the development and implementation of a care pathway. Care
pathways, also known as clinical pathways or critical pathways, are used worldwide for a
variety of patient groups. The European Pathway Association (E-P-A) defines a care pathway
as: "A complex intervention for the mutual decision making and organization of predictable
care for a well-defined group of patients during a well defined period. Defining
characteristics of pathways includes: an explicit statement of the goals and key elements of
care based on evidence, best practice and patient expectations; the facilitations of the
communication and coordination of roles, and sequencing the activities of the
multidisciplinary care team, patients and their relatives; the documentation, monitoring, and
evaluation of variances and outcomes; and the identification of relevant resources".
Very few prospective studies have been performed and published on the impact of pathways on
quality and efficiency of care. The European Quality of Care Pathways (EQCP)-study will
involve exacerbation of Chronic Obstructive Pulmonary Disease (COPD) to evaluate pathway
effectiveness. Literature shows that adherence to international guidelines with regard to
inhospital management of COPD exacerbation is low, especially in non pharmacological
treatment.11-19 Currently, only three non-randomized trials about the impact of a care
pathway for inpatient management of COPD exacerbation are published. The studies are
conducted between 1995 and 2001, and the methodology is doubtful. However the studies
indicate that a COPD exacerbation care pathway improves performance with regard to diagnostic
assessment and use of standing orders, and that it diminishes the number of
rehospitalisation, shortens length of stay (LOS) and reduces mortality.
In the context of the high volume of hospitalized COPD patients, high costs and high risk,
and the complex coordination of care among multiple caregivers, a care pathway could enhance
the quality of care in these patients by improving patient outcomes, promoting patient
safety, increasing patient satisfaction, improving multidisciplinary teamwork and optimizing
the use of resources.
The goal of the European Quality of Care Pathways (EQCP) study is:
- To evaluate the care pathway effectiveness in acute hospitals and their immediate link
with primary care;
- To evaluate the effect of care pathways on team processes and team perceived
organization of care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|